Roche, a provider of in-vitro diagnostic products, has launched cobas e 602 module for immunoassay testing as the latest addition to its cobas 8000 platform. The new cobas e 602 module allows customers to integrate immunoassay and clinical chemistry testing on a single platform.
Roche said that the product is available in Europe as well as in all countries recognising the CE mark in the Latin America and Asia-Pacific regions.
According to Roche, the cobas e 602 module, including Roche’s latest biomarker tests, runs more than 80 different immunoassays from high medical value tests for cardiac and infectious diseases to bone markers, rheumatoid arthritis, tumor markers and tests for maternal care with a throughput of 170 tests/hour.
Roche offers 7 additional configurations to the cobas 8000 modular analyzer series by combining the previously launched clinical chemistry modules with the immunoassay module for serum work area testing.
Roche added that cobas 8000 modular analyzer series is designed to meet the needs of high volume laboratories with about 3 to 15 million tests per year to deliver high quality results fast and efficiently from a single patient sample.
cobas 8000 compliments the cobas 6000 modular analyzer for medium-sized laboratories and the cobas 4000 systems for small workloads.
Daniel O’Day, chief operating officer of Roche Diagnostics, said: “With the recent launch of the clinical chemistry modules cobas c 701 and c502, we set a new standard in efficiency for high volume testing. The e602 module will further enhance our customers testing capability by seamlessly integrating clinical chemistry and immunoassay tests in one system.”